Pacific Biosciences of California, Inc. PACB · NASDAQ
$2.06 -3.74% (-$0.08)
Summary
28 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- Revenue growth is slowing: 7.6% a year over the last 3 years against 15% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 7.6% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $131.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 8
- Sell 1
Today's price within the analysts' price targets
The average target of $1.18 is 43% below today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 46%
- Consumable 28%
- Instrument 18%
- Service And Other 8.2%
By region
- Americas 32%
- UNITED STATES 30%
- EMEA 19%
- Asia Pacific 19%
Product brings in 46% of revenue. Consumable grew fastest, by 21% a year.
Segments in detail